<DOC>
	<DOCNO>NCT00835406</DOCNO>
	<brief_summary>The objective study compare rate extent absorption alendronate sodium 70 mg tablet ( test ) versus Fosamax® 70 mg tablet ( reference ) administer single dose 70 mg fasting condition . A review pharmacokinetic data demonstrates Alendronate Sodium Tablets , 70 mg , manufacture distribute TEVA Pharmaceuticals USA bioequivalent Fosamax® Tablets , 70 mg , manufacture Merck Sharp &amp; Dohme , USA .</brief_summary>
	<brief_title>Alendronate Sodium 70 mg Tablet Versus Fosamax® Under Fasting Conditions .</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Subjects male , nonsmoker , 18 45 year age . Subjects ' weight within 15 % ideal body weight base Table `` Desirable Weight Adults '' , Metropolitan Life Insurance Company , 1983 Subjects read , sign , date Informed Consent Form prior study procedure . Subjects must complete screening procedure within 28 day prior administration study medication . Clinically significant abnormality find medical screening . Any history presence significant neurological , hepatic , renal , endocrine , cardiovascular , pulmonary , hematologic , immunologic , psychiatric metabolic disease . Any clinically significant history ongoing gastrointestinal problem problem know interfere absorption , distribution , metabolism excretion drug ( e.g . chronic diarrhea , inflammatory bowel disease ) . Clinically significant illness within 4 week administration study medication . Abnormal laboratory test judge clinically significant . ECG vital sign abnormality ( clinically significant ) . History allergic reaction alendronate relate drug ( e.g . clodronate , etidronate pamidronate ) . History allergic reaction heparin . Any food allergy , intolerance , restriction , special diet opinion medical subinvestigator , contraindicate subject 's participation study . Positive urine drug screen screen checkin period I . Positive test hepatitis B , hepatitis C HIV screen . Use investigational drug participation investigational study , within 30 day prior administration study medication . Recent donation plasma ( 500 mL ) within 7 day recent donation significant loss whole blood ( 450 mL ) within 56 day prior administration study medication . History significant alcohol abuse within six month screen visit indication regular use two unit alcohol per day ( 1 Unit = 150mL wine 360 mL beer 45 mL alcohol 40 % ) . Recent history drug abuse use illegal drug : use soft drug ( marijuana , pot ) within 3 month screen visit hard drug ( cocaine , phencyclidine ( PCP ) , crack ) within 1 year screen visit . Subjects use tobacco within 90 day start study . Subjects take prescription medication 14 day precede administration study medication overthecounter product 7 day precede administration study medication , except topical product without systemic absorption . Subjects take drug know induce inhibit hepatic drug metabolism within 30 day prior administration study medication ( examples inducer : barbiturate , carbamazepine , phenytoin , glucocorticoid , rifampin/rifabutin ; examples inhibitor : antidepressant , cimetidine , diltiazem , erythromycin , ketoconazole , MAO inhibitor , neuroleptic , verapamil , quinidine ) . Subjects undergone clinically significant surgery 4 week prior administration study medication . Any reason , opinion medical subinvestigator , would prevent subject participate study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>